Our group and others previously developed a multiomics biomarker for cancer immunotherapy combining tumor alteration burden, PD-L1 expression, and CTL infiltration.18,19 The present study adds the lncRNA score to this biomarker, potentially increasing and substantially improving the ability to predict immunotherapeutic benefit on OS, likely because of the additional information regarding immune dysfunction provided by the lncRNA signature. This evidence concerns the gene CD274 and cancer.